What did German Health Minister Nina Warken say about exempting drugmakers from proposed cost-cutting legislation?

German Health Minister Nina Warken stated that drugmakers will not be exempted from the proposed cost-cutting measures, emphasizing that 'every sector must play its part in this reform' and that exempting the pharmaceutical industry was 'out of the question'.

How did the minister respond to pharmaceutical companies' concerns about reduced investment and delayed launches of innovative medicines in Germany?

Warken acknowledged that many pharmaceutical companies are under pressure and that the planned legislation would not bring them extra revenue, but she affirmed that Germany remains an attractive location for the industry due to statutory health insurance reimbursement, clinical trial opportunities, and the fact that 'compared to other European countries, we have the fastest access to innovative medicines in Germany.'

Drugmakers will not be exempt from cost cuts, says German health minister

Jun 12, 2026

German Health Minister Nina Warken confirmed drugmakers will not be exempt from new cost-cutting legislation aimed at capping health insurance expenses. Consequently, major firms like Eli Lilly and Pfizer are reviewing or slashing investments in Germany due to the policy uncertainty.

reuters

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026